Skip to main content
Erschienen in: Journal of Cancer Survivorship 4/2008

01.12.2008

Distress persists in long-term brain tumor survivors with glioblastoma multiforme

verfasst von: Stephen T. Keir, Margaret M. Farland, Eric S. Lipp, Henry S. Friedman

Erschienen in: Journal of Cancer Survivorship | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Glioblastoma multiforme (GBM) is the most common and aggressive type of primary brain tumor. The prognosis for GBM patients is extremely poor with an estimated median survival of 12 months. Despite this statistic, a number of GBM patients are living longer than in the past as new detection and treatment approaches are used. However, little is known about the psychological correlates of this disease. To address this issue we investigated distress and its sources in long-term survivors (LTS) of this disease.

Materials and methods

Participants were asked to complete the National Comprehensive Cancer Network’s (NCCN) Distress Thermometer, a single-item rapid screening tool for distress. Participants were also asked to designate sources of distress from a 34-item list developed by the NCCN. Distress scores and sources of distress for long-term GBM survivors (>18 months) were compared to patients diagnosed within the last 18 months (<18 months).

Results

Eight-three brain tumor patients participated in this study. Fifty-nine percent of LTS met the ≥ 4 cut-off score for distress (M = 4.61, SD 3.12) as compared to 49% of patients diagnosed less than 18 months (M = 3.93, SD = 2.21; x2 = 0.406, NS), LTS reported fewer items of concern while more LTS reported being distressed.

Conclusions

This study indicates that LTS of GBM report experiencing distress at similar levels to other brain tumor patients. Level of distress for LTS is directly related to the total number of concerns in both emotional and physical domains.

Implications for cancer survivors

Regardless of LTS status, distress continues to be a part of the disease trajectory for many GBM patients. As such, attention to distress in these survivors of a major life threatening disease is warranted in follow up surveillance visits.
Literatur
1.
Zurück zum Zitat Society BT. Professional resources, brain tumor facts and statistics. In. 2008. Society BT. Professional resources, brain tumor facts and statistics. In. 2008.
2.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. CA: a Cancer Journal for Clinicians. Cancer Statistics 2006;56:106–30. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. CA: a Cancer Journal for Clinicians. Cancer Statistics 2006;56:106–30.
4.
Zurück zum Zitat Shaw EG, Seiferheld W, Scott C, Coughlin C, Leibel S, Curran W, et al. Reexamining the radiation therapy oncology group (RTOG) recursive partitioning analysis (RPA) for glioblastoma multiforme (GBM) patients. International Journal of Radiation Oncology, Biology, Physics 2003;57:S135–S6. doi:10.1016/S0360-3016(03)00843-5. Shaw EG, Seiferheld W, Scott C, Coughlin C, Leibel S, Curran W, et al. Reexamining the radiation therapy oncology group (RTOG) recursive partitioning analysis (RPA) for glioblastoma multiforme (GBM) patients. International Journal of Radiation Oncology, Biology, Physics 2003;57:S135–S6. doi:10.​1016/​S0360-3016(03)00843-5.
5.
Zurück zum Zitat Medscape. Brain Cancer Incidence and Survival. In: WebMD. 2008. Medscape. Brain Cancer Incidence and Survival. In: WebMD. 2008.
6.
Zurück zum Zitat Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ Jr, et al. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening—a report from the American society of clinical oncology. Journal of Clinical Oncology 2007;5:46–162. doi:10.1200/JCO.2006.09.7030. Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, Curran WJ Jr, et al. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening—a report from the American society of clinical oncology. Journal of Clinical Oncology 2007;5:46–162. doi:10.​1200/​JCO.​2006.​09.​7030.
13.
Zurück zum Zitat Keir ST, Calhoun-Eagan RD, Swartz JJ, Saleh OA, Friedman HS. Screening for distress in patients with brain cancer using the NCCN’s rapid screening measure. Psychooncology 2007. Keir ST, Calhoun-Eagan RD, Swartz JJ, Saleh OA, Friedman HS. Screening for distress in patients with brain cancer using the NCCN’s rapid screening measure. Psychooncology 2007.
18.
Zurück zum Zitat Patterson H. Nobody can afford a brain tumor: the financial impact of brain tumors on patients and families. A summary finding. San Francisco, CA; 2007. Patterson H. Nobody can afford a brain tumor: the financial impact of brain tumors on patients and families. A summary finding. San Francisco, CA; 2007.
19.
Zurück zum Zitat Pelletier G, Verhoef MJ, Khatri N, Hagen N. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. Journal of Neuro-Oncology 2002;57:41–9. doi:10.1023/A:1015728825642.PubMedCrossRef Pelletier G, Verhoef MJ, Khatri N, Hagen N. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. Journal of Neuro-Oncology 2002;57:41–9. doi:10.​1023/​A:​1015728825642.PubMedCrossRef
26.
Zurück zum Zitat NCCN practice guidelines for the management of psychosocial distress. National Comprehensive Cancer Network. Oncology. 1999;13:113–147. Williston Park. NCCN practice guidelines for the management of psychosocial distress. National Comprehensive Cancer Network. Oncology. 1999;13:113–147. Williston Park.
27.
Zurück zum Zitat Akizuki N, Akechi T, Nakanishi T, Yoshikawa E, Okamura M, Nakano T, et al. Development of a brief screening interview for adjustment disorders and major depression in patients with cancer. Cancer 2003;97:2605–13. doi:10.1002/cncr.11358.PubMedCrossRef Akizuki N, Akechi T, Nakanishi T, Yoshikawa E, Okamura M, Nakano T, et al. Development of a brief screening interview for adjustment disorders and major depression in patients with cancer. Cancer 2003;97:2605–13. doi:10.​1002/​cncr.​11358.PubMedCrossRef
29.
Zurück zum Zitat Trask PC, Paterson A, Riba M, Brines B, Griffith K, Parker P, et al. Assessment of psychological distress in prospective bone marrow transplant patients. Bone Marrow Transplantation 2002;29:917–25. doi:10.1038/sj.bmt.1703557.PubMedCrossRef Trask PC, Paterson A, Riba M, Brines B, Griffith K, Parker P, et al. Assessment of psychological distress in prospective bone marrow transplant patients. Bone Marrow Transplantation 2002;29:917–25. doi:10.​1038/​sj.​bmt.​1703557.PubMedCrossRef
31.
32.
Zurück zum Zitat Friedman H, Szalavitz M. What is "hope" for a patient with a deadly brain tumor? cerebrum. The Dana Farber Forum on Brain Science 2003;5:7–18. Friedman H, Szalavitz M. What is "hope" for a patient with a deadly brain tumor? cerebrum. The Dana Farber Forum on Brain Science 2003;5:7–18.
33.
Zurück zum Zitat Curren JR. Support needs of brain tumour patients and their carers: the place of a telephone service. International Journal of Palliative Nursing 2001;7:331–7.PubMed Curren JR. Support needs of brain tumour patients and their carers: the place of a telephone service. International Journal of Palliative Nursing 2001;7:331–7.PubMed
Metadaten
Titel
Distress persists in long-term brain tumor survivors with glioblastoma multiforme
verfasst von
Stephen T. Keir
Margaret M. Farland
Eric S. Lipp
Henry S. Friedman
Publikationsdatum
01.12.2008
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 4/2008
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-008-0069-7

Weitere Artikel der Ausgabe 4/2008

Journal of Cancer Survivorship 4/2008 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.